Draft:Monod Bio
Submission declined on 18 December 2023 by Ldm1954 (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: Too soon. Just having a single article in Nature is not enough. Ldm1954 (talk) 16:16, 18 December 2023 (UTC)
- Comment: External links in text are unsuitbale for wiki.
Corrected: Removed and turned into red links. They may be placed in an external links section, but they cannot be a part of the text so as to not spam the reader. microbiologyMarcus (petri dish·growths) 14:13, 12 December 2023 (UTC)
| Company type | Startup company |
|---|---|
| Industry | Biotechnology |
| Founders | Daniel Adriano Silva Manzano, David Shoultz, Alfredo Quijano Rubio, David Baker |
| Headquarters | Seattle, Washington , |
Key people | Daniel Adriano Silva Manzano (CEO), David Shoultz (COO), Alfredo Quijano Rubio (CSO) |
| Website | monod.bio |
Monod Bio is an American biotechnology company based in Seattle, Washington. The company is developing novel clinical diagnostics and biotechnology tools using AI-powered de novo protein design.[1]
History[edit]
The company was founded by Daniel Adriano Silva Manzano, David Shoultz, and Alfredo Quijano Rubio as a spin-out from the University of Washington Institute for Protein Design and the lab of Dr. David Baker.[1] Dr. Baker is a co-founder and close advisor.[1]
It was originally housed in the CoMotion Labs biotech incubator at University of Washington before relocating to a separate facility in South Lake Union.[2][1] In 2022, Monod Bio completed a seed round financing of $25 million dollars with Matrix Capital Management as a lead investor and participation from the Global Health Investment Corporation Cerano Management, The Washington Research Foundation, Boom Capital Ventures, Sahsen Ventures, and Pack Ventures.[1][3][4][5]
In August 2023, Alfredo Quijano Rubio received Health and Business Insider's 30 under 40 award for his work with the company.[6]
Research[edit]
Monod Bio utilizes the "Rosetta" protein engineering software developed at the Institute for Protein Design to develop biosensors.[1] These sensors emit bioluminescent signals in the presence of an analyte, which was showcased in a Nature publication in 2021.[7] The two-protein (known as lucCage and lucKey), modular system emits light when the proteins bind, causing an attached luciferase to emit light.[7]
In December 2022, the lucCage-lucKey biosensor system was featured in a new article in Advanced Materials, where the Baker Lab--featuring CSO, Alfredo Quijano Rubio--collaborated with the Silk Lab at Tufts University.[8] This collaboration theorized the incorporation of the biosensors into silk fibers, allowing for detection of proteins upon contact with the fibers.[8] In February 2023, Monod Bio announced a publication in Nature introducing its de novo protein design platform for the creation of its novel luciferase, LuxSit.[9][10]
References[edit]
- ^ a b c d e f Schubert, Charlotte (15 August 2022). "Institute for Protein Design spinout Monod Bio raises $25M for molecular biosensors". GeekWire. Retrieved 7 December 2023.
- ^ Schubert, Charlotte (2 August 2023). "Seattle startups move into growing science cluster in South Lake Union". GeekWire. Retrieved 7 December 2023.
- ^ Gormley, Brian (15 August 2022). "Biotech Startup Monod Bio Collects $25 Million Seed Financing". Wall Street Journal Venture Capital. Retrieved 7 December 2023.
- ^ Pratap, Aayushi (15 August 2022). "David Baker lab spinout scores seed funding to build a biosensor from engineered protein". Endpoints News. Retrieved 7 December 2023.
- ^ Vedantam, Keerthi (15 August 2022). "Monod Bio Raises $25M To Quickly Daignose Diseases". Crunchbase News. Retrieved 7 December 2023.
- ^ Brueck, Hilary (17 August 2023). "30 Leaders Under 40 Changing Healthcare in 2023". Axel Springer SE. Business Insider. Retrieved 7 December 2023.
- ^ a b Quijano-Rubio, Alfredo (27 January 2021). "De novo design of modular and tunable protein biosensors". Nature. 591 (7850): 482–487. doi:10.1038/s41586-021-03258-z. PMC 8074680. PMID 33503651.
- ^ a b d'Amone, Luciana; Matzeu, Guisy; Quijano-Rubio, Alfredo; Callahan, Gregory; Napier, Bradley; Baker, David; Omenetto, Fiorenzo (9 December 2022). "Reshaping de Novo Protein Switches into Bioresponsive Materials for Biomarker, Toxin, and Viral Detection". Advanced Materials. 35 (11). doi:10.1002/adma.202208556. Retrieved 20 December 2023.
- ^ Ha, Kimberely (22 February 2023). "Monod Bio Announces Publication in Nature Highlighting De Novo Protein Technology Platform for the Creation of Novel Luciferases". Berkshire Hathaway. Business Wire. Retrieved 7 December 2023.
- ^ Yeh, Andy (22 February 2023). "De novo design of luciferases using deep learning". Nature. 614 (7949): 774–780. doi:10.1038/s41586-023-05696-3. PMC 9946828. PMID 36813896.
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.